Eurofins Strengthens Its Specialty Clinical Diagnostics Footprint with the Acquisition of the Genoma Laboratory Group in Italy
June 26 2017 - 1:30AM
Business Wire
Regulatory News:
Eurofins Scientific (Paris:ERF) (EUFI.PA), a global leader in
bio-analytical testing, and one of the world leaders in genomic
services, announces that it has signed an agreement to acquire
Genoma Group Srl (“Genoma”), one of the leading specialty
diagnostics testing providers in Italy. The transaction is expected
to close in the next few weeks, subject to customary closing
conditions.
With 20 years of clinical testing innovation, Genoma offers a
wide range of specialty diagnostic testing services, and has
developed a strong reputation in molecular biology and
cytogenetics. Specifically, the company is a pioneer in
non-invasive pre-natal testing (NIPT) in Italy, and leads the
industry in innovative diagnostic tests in oncology. Genoma employs
about 100 staff across its 2 main sites in Rome and Milan, and
generates annual revenues in excess of EUR 20m.
The company serves hospitals, physicians and other laboratories
which outsource the more complex diagnostic tests to Genoma. Given
the ongoing consolidation in the clinical testing sector in Europe,
the company is well-positioned to leverage and strengthen its
footprint in the specialty diagnostic testing sector. This
acquisition therefore provides Eurofins a strong entry platform
into the clinical testing market in Italy, and strengthens the
Group’s footprint in the specialty diagnostic testing market in
Europe. In return, Genoma should be able to further develop its
portfolio of tests and services, as well as consolidate their
client reach, by leveraging the Group’s renowned capabilities in
genomic testing and its international presence.
Comment from Dr. Francesco Fiorentino, Genoma CEO and founder:
"We are excited to be joining Eurofins and look forward to the next
phase of our development within the Group. We are confident that
with access to Eurofins’ global network, we should be able to
expand our geographic footprint, and achieve an improved
international positioning of our analytical portfolio and molecular
diagnostics services."
Comment from Dr. Gilles Martin, Eurofins CEO: “The acquisition
of Genoma reinforces Eurofins’ growing footprint in the specialty
clinical diagnostics market, with innovative services with high
positive impact for patient care. This transaction should enable
the Group to continue deploying its technical know-how and
proprietary technologies throughout Europe. In return, Genoma
should benefit from access to the full capabilities of the Eurofins
network.”
For more information, please visit
www.eurofins.com
Notes for the editor:
Eurofins – a global leader in bio-analysis
Eurofins Scientific through its subsidiaries (hereinafter
sometimes “Eurofins” or “the Group”) believes it is the world
leader in food, environment and pharmaceutical products testing and
that it is also one of the global independent market leaders in
certain testing and laboratory services for agroscience, genomics,
discovery pharmacology and for supporting clinical studies. In
addition, Eurofins is one of the key emerging players in specialty
clinical diagnostic testing in Europe and the USA. With over 28,000
staff in 310 laboratories across 39 countries, Eurofins offers a
portfolio of over 130,000 analytical methods for evaluating the
safety, identity, composition, authenticity, origin and purity of
biological substances and products, as well as for innovative
clinical diagnostic. The Group objective is to provide its
customers with high-quality services, accurate results on time and
expert advice by its highly qualified staff.
Eurofins is committed to pursuing its dynamic growth strategy by
expanding both its technology portfolio and its geographic reach.
Through R&D and acquisitions, the Group draws on the latest
developments in the field of biotechnology and analytical chemistry
to offer its clients unique analytical solutions and the most
comprehensive range of testing methods.
As one of the most innovative and quality oriented international
players in its industry, Eurofins is ideally positioned to support
its clients’ increasingly stringent quality and safety standards
and the expanding demands of regulatory authorities around the
world.
The shares of Eurofins Scientific are listed on the Euronext
Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg
ERF FP).
Important disclaimer:
This press release contains forward-looking statements and
estimates that involve risks and uncertainties. The forward-looking
statements and estimates contained herein represent the judgement
of Eurofins Scientific’ management as of the date of this release.
These forward-looking statements are not guarantees for future
performance, and the forward-looking events discussed in this
release may not occur. Eurofins Scientific disclaims any intent or
obligation to update any of these forward-looking statements and
estimates. All statements and estimates are made based on the
information available to the Company’s management as of the date of
publication, but no guarantee can be made as to their validity.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170625005006/en/
Eurofins ScientificInvestor RelationsPhone: +32 2 766
1620E-mail: ir@eurofins.com
Enerplus (NYSE:ERF)
Historical Stock Chart
From Mar 2024 to Apr 2024
Enerplus (NYSE:ERF)
Historical Stock Chart
From Apr 2023 to Apr 2024